Volver

Regeneron Pharmaceuticals Inc

RE Ticker: REGN ISIN: US75886F1075

Añadir al portafolio Análisis de cartera en 2min

Stock Large-cap Dividend payer

Capitalización

71,99 MM $

P/E

17,18

Forward P/E

14,58

Profit margin

31,07%

Revenue growth QoQ

10,30%

Div. yield

0,53%

Beta

0,27

828,50 $ -0,66%

Precio a fecha de 2026-08-24 · NASDAQ

Rendimiento por período

Rendimientos acumulados

1 Month +24,33%

6 Months +7,58%

1 Year +45,49%

5 Years +4,67% p.a.+25,62%

10 Years +7,68% p.a.+109,40%

Since inception +14,23% p.a.+2 676,62%

Rendimientos por año

YTD +7,75%

2025 +8,96%

2024 -18,90%

2023 +21,73%

2022 +14,25%

2021 +30,72%

Key stats

Market cap

71,99 MM

P/E

17,18

Dividend yield

0,53%

Beta

0,27

52-week range

641.18 - 1,209.65

50-day MA

690,94

200-day MA

904,77

Section 1

Business overview

Company profile data from fundamentals.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sector Healthcare

Industry Biotechnology

Country United States

Exchange NASDAQ

Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 15,95%

ROA 7,31%

Profit margin 31,07%

Operating margin 26,91%

PEG ratio 0,98

Revenue/share TTM 131,62

Revenue TTM 14,20 MM

EBITDA 4,63 MM

Gross profit TTM 7,10 MM

Beta 0,27

Valuation

Trailing P/E 17,18

Forward P/E 14,58

P/B 2,45

P/S 5,07

EV/EBITDA 12,35

EV/Revenue 4,62

ESG Scores

Total ESG 22,3

Environment 1,5

Social 13,9

Governance 5,9

Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 42,64

Quarterly earnings growth -20,80%

Revenue TTM 14,20 MM

Reported quarters 123

Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 0,53%

Forward annual div. yield 0,53%

Dividend per share 0,0000

Payout ratio 1,93%

Ex-dividend date 2025-02-20

Last split date 0000-00-00

Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 1.042,95 $

Analyst rating 4.16

Ownership & short interest

Shares outstanding 107,51 M

Shares float 103,00 M

Institutional ownership 91,40%

Insider ownership 1,58%

Short ratio 2,84

Short % of float 2,48%

Details

Instrument metadata and source update timestamps.

Symbol REGN

Name Regeneron Pharmaceuticals Inc

Asset type STOCK

Exchange NASDAQ

Currency USD

ISIN US75886F1075

Country USA

Code + exchange REGN.NASDAQ

Last price date 2025-03-21

Fundamentals updated 2025-03-23

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.